A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment

Trial Profile

A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Amikacin (Primary)
  • Indications Mycobacterium avium complex infections; Respiratory tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CONVERT
  • Sponsors Insmed
  • Most Recent Events

    • 03 Aug 2017 According to an Insmed media release, the company expects to report top-line data from this trial in September plus or minus one month.
    • 24 May 2017 Trial design presented at the 113th International Conference of the American Thoracic Society
    • 23 Feb 2017 According to an Insmed media release, the company expects to report the top-line data from this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top